DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypersensitivity reaction disease — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypersensitivity reaction disease maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypersensitivity reaction disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nei like DNA glycosylase 3 (NEIL3) — NEIL3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7JL5 · 2.6 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2012 review of hypersensitivity reactions to antineoplastic agents notes that almost all chemotherapeutic drugs can cause such reactions, with platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins carrying increased risk. Clinical manifestations are variable and unpredictable, affecting skin, lungs, heart and gastrointestinal tract. The mechanism is not fully understood. Diagnosis relies on signs, symptoms and skin testing. Management depends on reaction severity, the need to continue treatment and the availability of alternatives. Desensitisation protocols are described as a noteworthy alternative that can allow re-initiation of therapy with the causative agent, but their use must be assessed individually, weighing risks and benefits. No concrete numbers on incidence, response rates or survival are given.
A 2008 review of drug allergies states that drug hypersensitivity reactions are unpredictable side effects, not rare, and a frequent worry for clinicians. It reports that clinical and pathological data are scarce, as are diagnosis centres. The mechanisms are multiple and a firm diagnosis is often possible, but further research is needed. No concrete numbers are provided.
A 2016 report on drug hypersensitivity syndrome (DHS) describes it as a drug-induced reaction of extremely severe clinical course and serious prognosis, posing major diagnostic problems and frequently unrecognised by clinicians. The authors present information on epidemiology, aetiology, pathogenesis, clinical picture, diagnostics and treatment, but the abstract gives no concrete numbers on incidence, mortality or treatment outcomes. It is the first report on this syndrome in Poland.
What is still missing: large prospective studies with standardised diagnostic criteria, validated biomarkers to predict or confirm hypersensitivity, and randomised trials comparing desensitisation protocols against alternative regimens. Funding for basic research into mechanisms and for multicentre diagnostic networks is lacking. Patient stratification by drug class, genetic risk and reaction phenotype has not been achieved.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Farmacia Hospitalaria · 2012 · 12 citations · open access
Revisión de las reacciones de hipersensibilidad a antineoplásicos
AbstractOBJECTIVE: To review the characteristics and management of hypersensitivity reactions caused by antineoplastic agents. METHOD: We conducted a search in the Pubmed and EMBASE databases for the last 10 years. RESULTS: Almost all chemotherapeutic agents have the potential to cause hypersensitivity reactions, but some groups have been associated with increased risk, such as platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins. The clinical manifestations of these reactions are variable and unpredictable, including symptoms affecting the skin and the pulmonary, cardiac and gastrointestinal systems. The mechanism associated with their development is not yet fully understood. Diagnosis is based on patients' signs and symptoms and skin testing. The management of patients who suffer a hypersensitivity reaction to a chemotherapeutic agent varies with the severity of the reaction, the need to continue treatment, and the availability of alternative therapies. CONCLUSIONS: Due to a progressive increase in the use of chemotherapeutic agents an increased incidence of hypersensitivity reactions is to be expected. Desensitisation protocols are a noteworthy alternative that make it possible to re-initiate patients' therapy with the causative agent of the hypersensitivity reaction. Their use should be assessed individually, weighing risks and benefits.
Expert Opinion on Drug Safety · 2008 · 6 citations
Drug allergies – unknown dangers to patients
AbstractBACKGROUND: Drug hypersensitivity reactions are unpredictable side effects. They are a frequent worry for clinicians of all disciplines. Available clinical and pathological data are scarce, as are diagnosis centers. OBJECTIVE: To review the unmet needs in drug hypersensitivity clinical and basic research. METHODS: A literature search was performed and expert opinions in the field were collected. RESULTS/CONCLUSION: Drug hypersensitivity reactions are not so rare adverse events. The mechanisms are multiple and a firm diagnosis is often possible. However, further research is needed.
AbstractEarly diagnosis of an adverse cutaneous drug reaction (ACDR) is the key to preventing a more severe and life-threatening drug reaction. ACDRs can range from mild rashes to life-threatening events. ACDRs are classified as immunologic and nonimmunologic etiologies. Drug hypersensitivity is an immune mediated response. True hypersensitivity adverse drug reactions mimic many disease states and can involve any organ system (S. ). A thorough history is critical when the patient presents with systemic symptoms in addition to a dermatological response that does not display common distributions and lesions. Medications previously prescribed and taken by patients may produce a delayed immune mediated response that can result in multiorgan syndrome, Stevens-Johnson syndrome, or toxic epidermal necrolysis.
AbstractThe drug hypersensitivity syndrome (DHS) is a drug-induced reaction of an extremely severe clinical course and serious prognosis. It poses major diagnostic problems and is frequently unrecognized by clinicians. Based on literature data, the authors have presented the information on epidemiology, etiology, pathogenesis, clinical picture, diagnostics and treatment of DHS. This is the first report in Poland concerning this clinical interdisciplinary syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
